The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Hi mate
I don't need the links as quite capable at TA .
No where near a bowl ..
You have more of a Ladel from what I see which is really clutching at straws . .
Seen many a perfect C@H over my years which generally play out .. .. even a bullflag can fail then it's back to engulfing candles for yr trades
Pj
Iceman
No cup and handle mate
What you have is a bullflag giving you an uplift of 13p odd once it breaks 21p.
So initial target is 32 - 35p
Tightening of the bollys .crossovers and being ove4sold will all help the move . .
Volumes the key
PJ
Rb...As in same old *******s suzy has been been saying since xmas ...time and time again I asked her to in for. Shareholders of updates on how things are going at least how much these goons are trying to raise .always the same answer lol
I hope that everyone who has questions comes to the AGM! I don’t mind the Spanish Inquisition as long as they are asking genuine questions. We have all worked as hard as we can for the benefit of shareholders, so I know that we can hold our heads high and answer anything that is asked completely genuinely. Obviously we can’t give commercially sensitive details, which will probably annoy some people, but we can explain why those details are sensitive. I’m not the sort of person who hides from difficult questions and hopes the questioner just goes away. I’d far rather people just turn up and ask the questions.
We are actively carrying out preclinical experiments on both VAL301 and BC201; this programme of preclinical experiments will better define the future development plans of these projects – when there are updates to provide on these then they will be made, however at the moment, the data generated is confidential until it is completed and can be assessed for use in patent filings. If we publish data to our shareholders, then the same data cannot later be used for new patent applications, as patent applications have to pass the “novelty” and “inventiveness” tests. That is that at the time that the patent application is made, the invention described has to be completely new, and non-obvious to someone “skilled in the art”. If the data is already published before the patent is filed, then the invention will be deemed obvious to the skilled reader and the patent will not be granted.
That really depends on the details that TheoremRx give us in their update – remember their current period hasn’t yet expired, so the extension is from then, not from right now. We expect their update to show the progress and the length of time needed to get to where they need to be.
Remember as well that we’re not the only party involved, everyone seems convinced that I’m just being soft on them, but any agreement also has to have approval from CRT. We’ve previously mentioned that CRT have been involved the whole way through, and we even had to re-state our license agreement with CRT in order to enable the arrangement. CRT have as much interest as we do in making sure the project is progressed appropriately, so rest assured that I’m never operating alone from any angle.
Hi Pete,
We can only release details that they agree we can release – obviously if anything might influence their investors to change course, then we will not be publicly giving those details. It’s not in anyone’s interests for us to say something that destroys the deal, even if it makes shareholders happy for a day or two. We expect that there will be some additional extra information that we can give openly, as well as sharing our own opinions on the information that we’re given.
We will be making the point clear to them that we do need to be as transparent as possible to our shareholders and they will help us to formulate the public announcement.
They are the right partner. If we were to look for an alternative it would be highly likely to be a similar outfit as quite simply the project needs further innovative work carried out to extend the patent life in order for it to progress. Starting again with a new partner would just be re-starting the clock. However, with that in mind, they know that me being involved in working with their science team works both ways - the project and plans are being built by both teams, regardless of who ends up running them.
The reason we added the slide showing the stages of progression of a drug candidate through trials against the patent timeline in all our recent presentations was in order to encourage our shareholders to understand the need for 201 to have its patents revamped. The 201 trial data is excellent, it shows a well tolerated, safe drug with a good indication of disease impact. However with the key patents filed in 2008, it needs a completely new innovation to move forwards and reach the market with patent protection still in place. That is the role for small biotechs, SPVs and academics, it’s not something big Pharma routinely do.